Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q3 2013 · 10-Q
Revenue$400.00K$400.00K+233.3% vs Q3 2012 Net Income-$22.91M-$22.91MN/M vs Q3 2012 EPS Diluted-$0.65-$0.65N/M vs Q3 2012 Operating Income-$15,452,000N/M Free Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-3863.0%+7588.7 pt vs Q3 2012
Net margin-5727.5%+8018.3 pt vs Q3 2012
ended Sep 30, 2013 · filed Nov 15, 2013 · 46 d after period end